Press release
Leuven, Belgium, 23 May 2018 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group (EASDec) Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland.
The presentations will provide an overview of the extensive preclinical evidence supporting the potential benefits of its two promising pipeline candidates THR-317, a humanized monoclonal antibody neutralizing placental growth factor (PIGF), and THR-149, a plasma kallikrein inhibitor, in the treatment of diabetic macula edema (DME).
Dr Jean Feyen, will present on THR-317, currently in a Phase 2 study in combination with anti-VEGF ranibizumab for the treatment of DME. In pre-clinical models, anti-PlGF has shown to reduce DME disease hallmarks; it has demonstrated anti-angiogenic properties as well as potential additional benefits compared to VEGF inhibitors (current standard of care), including anti-inflammation.
Dr Tine Van Bergen will present on THR-149, which is on track to enter Phase 1 clinical studies for the treatment of DME. Preclinical studies have demonstrated the potency and efficacy of bicyclic peptide inhibitors of PKal, such as THR-149, via a VEGF-independent pathway.
Details of the presentations are as follows:
Presenter: Jean Feyen Title: Neutralization of placental growth factor reduces retinal inflammation in diabetic animal models Date: Saturday 26 May 2018 Time: 12.14 Location: Riddel Hall, Centre for Experimental Medicine, Queen's University Belfast
Presenter: Tine Van Bergen Title: Targeting plasma kallikrein with a novel bicyclic peptide inhibitor reduces retinal leakage in a diabetic rat model Date: Saturday 26 May 2018 Time: 12.27 Location: Riddel Hall, Centre for Experimental Medicine, Queen's University Belfast
EASDec aims to promote the advancement of knowledge of all aspects of diabetic retinopathy, including epidemiology, pathology, pathophysiology, investigation and treatment through active collaboration between ophthalmologists and diabetologists.
END
For further information please contact:
| ThromboGenics Wouter Piepers, Global Head of Corp Coms & Investor relations +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com | Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/ Isabelle Andrews Tel: +44 20 7638 9571 thrombogenics@citigatedewerogerson.com |
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
ThromboGenics' clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME), which is in an ongoing Phase 2 clinical study in combination Lucentis®, and THR-149, a plasma kallikrein inhibitor which is targeted to enter the clinic in Q2 2018. Another candidate, THR-687 (an integrin antagonist) is in late-stage preclinical development for the treatment of diabetic retinopathy and DME. THR-687 is expected to enter the clinic around mid-2018. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.
ThromboGenics owns the global rights to JETREA ® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (outside the US).
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
